Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Autor: Cezary Szczylik, Anna Waśko-Grabowska, Jakub Żołnierek, Beata Obrocka, Paweł Nurzyński, Sylwia Oborska, Ewa Kuszatal, Przemysław Langiewicz
Rok vydání: 2009
Předmět:
Oncology
Compassionate Use Trials
Male
Cancer Research
Indoles
Pyridines
urologic and male genital diseases
Placebos
Drug Delivery Systems
Renal cell carcinoma
Antineoplastic Combined Chemotherapy Protocols
Sunitinib
Medicine
Randomized Controlled Trials as Topic
Benzenesulfonates
Bone metastasis
General Medicine
Middle Aged
Sorafenib
female genital diseases and pregnancy complications
Kidney Neoplasms
Treatment Outcome
Disease Progression
Female
medicine.drug
Adult
Niacinamide
medicine.medical_specialty
Bone Neoplasms
Clinical Trials
Phase II as Topic
Internal medicine
Carcinoma
Humans
Pyrroles
Carcinoma
Renal Cell
Aged
Retrospective Studies
business.industry
Phenylurea Compounds
Interferon-alpha
Sunitinib malate
medicine.disease
digestive system diseases
Surgery
Clinical Trials
Phase III as Topic
business
Kidney cancer
Kidney disease
Zdroj: Scopus-Elsevier
ISSN: 1432-1335
Popis: Introduction This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC). Methods The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w. Results Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047). Conclusion Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.
Databáze: OpenAIRE
Externí odkaz: